S&P 500   3,234.10 (-2.46%)
DOW   26,725.35 (-2.06%)
QQQ   264.69 (-2.86%)
AAPL   107.67 (-3.70%)
MSFT   201.35 (-2.93%)
FB   250.20 (-1.79%)
GOOGL   1,411.08 (-3.34%)
AMZN   3,003.10 (-4.02%)
NVDA   487.75 (-3.51%)
TSLA   382.31 (-9.88%)
BABA   273.08 (-0.80%)
CGC   14.51 (-9.54%)
GE   6.13 (-1.92%)
MU   50.19 (+0.99%)
AMD   75.10 (-3.35%)
T   27.91 (-2.10%)
F   6.68 (-1.47%)
ACB   5.18 (-29.23%)
GILD   63.19 (-0.33%)
NFLX   472.19 (-3.86%)
DIS   123.36 (-3.03%)
BAC   23.40 (-2.26%)
BA   152.22 (-2.92%)
S&P 500   3,234.10 (-2.46%)
DOW   26,725.35 (-2.06%)
QQQ   264.69 (-2.86%)
AAPL   107.67 (-3.70%)
MSFT   201.35 (-2.93%)
FB   250.20 (-1.79%)
GOOGL   1,411.08 (-3.34%)
AMZN   3,003.10 (-4.02%)
NVDA   487.75 (-3.51%)
TSLA   382.31 (-9.88%)
BABA   273.08 (-0.80%)
CGC   14.51 (-9.54%)
GE   6.13 (-1.92%)
MU   50.19 (+0.99%)
AMD   75.10 (-3.35%)
T   27.91 (-2.10%)
F   6.68 (-1.47%)
ACB   5.18 (-29.23%)
GILD   63.19 (-0.33%)
NFLX   472.19 (-3.86%)
DIS   123.36 (-3.03%)
BAC   23.40 (-2.26%)
BA   152.22 (-2.92%)
S&P 500   3,234.10 (-2.46%)
DOW   26,725.35 (-2.06%)
QQQ   264.69 (-2.86%)
AAPL   107.67 (-3.70%)
MSFT   201.35 (-2.93%)
FB   250.20 (-1.79%)
GOOGL   1,411.08 (-3.34%)
AMZN   3,003.10 (-4.02%)
NVDA   487.75 (-3.51%)
TSLA   382.31 (-9.88%)
BABA   273.08 (-0.80%)
CGC   14.51 (-9.54%)
GE   6.13 (-1.92%)
MU   50.19 (+0.99%)
AMD   75.10 (-3.35%)
T   27.91 (-2.10%)
F   6.68 (-1.47%)
ACB   5.18 (-29.23%)
GILD   63.19 (-0.33%)
NFLX   472.19 (-3.86%)
DIS   123.36 (-3.03%)
BAC   23.40 (-2.26%)
BA   152.22 (-2.92%)
S&P 500   3,234.10 (-2.46%)
DOW   26,725.35 (-2.06%)
QQQ   264.69 (-2.86%)
AAPL   107.67 (-3.70%)
MSFT   201.35 (-2.93%)
FB   250.20 (-1.79%)
GOOGL   1,411.08 (-3.34%)
AMZN   3,003.10 (-4.02%)
NVDA   487.75 (-3.51%)
TSLA   382.31 (-9.88%)
BABA   273.08 (-0.80%)
CGC   14.51 (-9.54%)
GE   6.13 (-1.92%)
MU   50.19 (+0.99%)
AMD   75.10 (-3.35%)
T   27.91 (-2.10%)
F   6.68 (-1.47%)
ACB   5.18 (-29.23%)
GILD   63.19 (-0.33%)
NFLX   472.19 (-3.86%)
DIS   123.36 (-3.03%)
BAC   23.40 (-2.26%)
BA   152.22 (-2.92%)
Log in
NASDAQ:QDEL

Quidel Stock Forecast, Price & News

$196.28
-2.70 (-1.36 %)
(As of 09/23/2020 03:45 PM ET)
Add
Compare
Today's Range
$188.61
Now: $196.28▼
$203.75
50-Day Range
$151.99
MA: $207.65▼
$301.96
52-Week Range
$55.25
Now: $196.28▼
$306.72
Volume25,171 shs
Average Volume954,216 shs
Market Capitalization$8.23 billion
P/E Ratio54.98
Dividend YieldN/A
Beta0.99
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Read More
Quidel logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.33 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:QDEL
Previous Symbol
CUSIP74838J10
CIK353569
Webwww.quidel.com
Phone858-552-1100

Debt

Debt-to-Equity RatioN/A
Current Ratio1.62
Quick Ratio1.12

Price-To-Earnings

Trailing P/E Ratio54.98
Forward P/E Ratio16.41
P/E GrowthN/A

Sales & Book Value

Annual Sales$534.89 million
Price / Sales15.39
Cash Flow$5.23 per share
Price / Cash Flow37.52
Book Value$13.44 per share
Price / Book14.60

Profitability

EPS (Most Recent Fiscal Year)$2.73
Net Income$72.92 million
Net Margins23.61%
Return on Equity33.86%
Return on Assets21.05%

Miscellaneous

Employees1,250
Outstanding Shares41,950,000
Market Cap$8.23 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$196.28
-2.70 (-1.36 %)
(As of 09/23/2020 03:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QDEL News and Ratings via Email

Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quidel (NASDAQ:QDEL) Frequently Asked Questions

How has Quidel's stock been impacted by Coronavirus?

Quidel's stock was trading at $89.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QDEL shares have increased by 118.9% and is now trading at $196.27.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Quidel?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Quidel.

When is Quidel's next earnings date?

Quidel is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Quidel.

How were Quidel's earnings last quarter?

Quidel Co. (NASDAQ:QDEL) released its quarterly earnings data on Thursday, July, 30th. The company reported $1.77 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.12 by $0.65. The firm earned $201.75 million during the quarter, compared to the consensus estimate of $201.40 million. Quidel had a return on equity of 33.86% and a net margin of 23.61%.
View Quidel's earnings history.

What guidance has Quidel issued on next quarter's earnings?

Quidel issued an update on its second quarter 2020 After-Hours earnings guidance on Monday, July, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $201-202 million, compared to the consensus revenue estimate of $178.91 million.

What price target have analysts set for QDEL?

6 brokers have issued twelve-month target prices for Quidel's stock. Their forecasts range from $75.00 to $363.00. On average, they anticipate Quidel's stock price to reach $189.67 in the next year. This suggests that the stock has a possible downside of 3.4%.
View analysts' price targets for Quidel.

Are investors shorting Quidel?

Quidel saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,070,000 shares, an increase of 13.1% from the August 15th total of 1,830,000 shares. Based on an average daily trading volume, of 1,400,000 shares, the short-interest ratio is presently 1.5 days. Approximately 5.6% of the company's shares are short sold.
View Quidel's Short Interest.

Who are some of Quidel's key competitors?

Some companies that are related to Quidel include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Anika Therapeutics (ANIK) and Antares Pharma (ATRS).
View all competitors.

What other stocks do shareholders of Quidel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include NVIDIA (NVDA), Shopify (SHOP), Docusign (DOCU), Tesla (TSLA), Paypal (PYPL), Square (SQ), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM) and Okta (OKTA).

Who are Quidel's key executives?

Quidel's management team includes the following people:
  • Mr. Douglas C. Bryant, Pres, CEO & Director (Age 61)
  • Mr. Randall J. Steward, Chief Financial Officer (Age 65)
  • Mr. Robert J. Bujarski, Sr. VP of Bus. Devel. & Gen. Counsel (Age 51)
  • Dr. Werner Kroll, Sr. VP of R&D (Age 62)
  • Mr. Edward Keith Russell, Sr. VP of Global Commercial Operations (Age 51)

What is Quidel's stock symbol?

Quidel trades on the NASDAQ under the ticker symbol "QDEL."

Who are Quidel's major shareholders?

Quidel's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.53%), FMR LLC (6.90%), ArrowMark Colorado Holdings LLC (2.04%), William Blair Investment Management LLC (1.30%), Cannell Peter B & Co. Inc. (1.25%) and New York State Common Retirement Fund (1.08%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Edward L Michael, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Matthew Strobeck, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll.
View institutional ownership trends for Quidel.

Which major investors are selling Quidel stock?

QDEL stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., New York State Common Retirement Fund, Vanguard Group Inc., BNP PARIBAS ASSET MANAGEMENT Holding S.A., Gabelli Funds LLC, Sei Investments Co., Public Employees Retirement Association of Colorado, and Gamco Investors INC. ET AL. Company insiders that have sold Quidel company stock in the last year include Edward Keith Russell, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, and Werner Kroll.
View insider buying and selling activity for Quidel.

Which major investors are buying Quidel stock?

QDEL stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, William Blair Investment Management LLC, Cannell Peter B & Co. Inc., Bank of New York Mellon Corp, Prudential Financial Inc., Principal Financial Group Inc., Principal Financial Group Inc., and Stephens Investment Management Group LLC. Company insiders that have bought Quidel stock in the last two years include Douglas C Bryant, Edward L Michael, and Matthew Strobeck.
View insider buying and selling activity for Quidel.

How do I buy shares of Quidel?

Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quidel's stock price today?

One share of QDEL stock can currently be purchased for approximately $196.27.

How big of a company is Quidel?

Quidel has a market capitalization of $8.23 billion and generates $534.89 million in revenue each year. The company earns $72.92 million in net income (profit) each year or $2.73 on an earnings per share basis. Quidel employs 1,250 workers across the globe.

What is Quidel's official website?

The official website for Quidel is www.quidel.com.

How can I contact Quidel?

Quidel's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 858-552-1100 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.